Moreover, in preclinical settings, the combination treatment targeting Tim-3 and PD-1 has exhibited a synergistic effect, reinvigorating T cell function and augmenting the overall anti-tumor immune response (187, 195). The gene discussed is PDCD1; the disease is neoplasm.